Marea is led by a dynamic team of scientists and company builders with deep knowledge and experience in #cardiometabolic diseases, human genetics, and adipocyte biology. We are #hiring for an innovative, data-driven Associate Director/Director of Project Management. Learn more and join our team here: https://lnkd.in/gzCRuppr
Marea Therapeutics
Biotechnology Research
San Francisco, CA 1,686 followers
The Next Frontier of Medicines for Cardiometabolic Diseases
About us
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The company’s lead program, MAR001, is in Phase 2 clinical development and has the potential to become a new treatment for patients who remain at high risk of severe cardiovascular disease due to elevated remnant cholesterol and metabolic dysfunction. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology.
- Website
-
www.mareatx.com
External link for Marea Therapeutics
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- San Francisco, CA
- Type
- Privately Held
Locations
-
Primary
Get directions
San Francisco, CA, US
Employees at Marea Therapeutics
Updates
-
We are #hiring for a candidate who's looking to support the development of transformational therapies for cardiometabolic diseases. Learn more about the role and join us here: https://lnkd.in/gyxNR_E2
-
-
Today, we announced the appointment of Ian Clements as our chief financial officer. With his extensive biopharmaceutical business leadership experience, Dr. Clements will be instrumental in driving our mission to accelerate the next generation of medicines for cardiometabolic diseases. Read more here: https://lnkd.in/gVwK_9Y2
-
-
Check it out: our co-founder and chief scientific officer Ethan Weiss joined Brad Loncar and BiotechTV to chat all things Marea, the risk of remnant cholesterol and how we are combining human genetics and adipose biology to develop novel therapies for patients at risk for heart attacks even after controlling classical risk factors such as #obesity and elevated LDL #cholesterol. Listen below.
𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐍𝐞𝐰𝐬: After exiting stealth mode with $190M today, Marea Therapeutics co-founder Ethan Weiss describes ANGPTL4 as a cardiometabolic target and more. He describes the difference between ANGPTL4 and ANGPLT3, the rationale for lowering remnant cholesterol, Marea's plans beyond this target, and his upcoming Timmerman Traverse hike for charity. Full video: https://lnkd.in/gQ9u7aQj BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Theragent Inc | NYSE | Allucent
-
Introducing Marea – a clinical-stage biotech on a mission to leverage large-scale human genetics and adipose biology to revolutionize the treatment of #cardiometabolic diseases. Cardiovascular disease remains the number one killer in the U.S. and globally despite many advances over the past few decades. With a clinical-stage pipeline of first-in-class treatments and a team of some of the industry’s most dynamic scientists and company builders, we’re ready to take this challenge head on. Learn more about Marea in the release below or visit us at www.mareatx.com. https://lnkd.in/eM5MrHtD